Biopharma M&A Surges in H1 2026, Led by Sun Pharma’s $11.75B Organon Acquisition and Merck KGaA’s $11.3B Bio-Techne Deal

Herbert Smith Freehills Kramer Global

Overview

The first half of 2026 witnessed a significant resurgence in pharmaceutical M&A activity, with several major acquisitions driving market consolidation. Notable transactions include Sun Pharma’s $11.75 billion acquisition of Organon and Merck KGaA’s $11.3 billion purchase of Bio-Techne. The CDMO sector also saw strategic moves, such as Lone Star Funds’ $2.2 billion acquisition of Lonza’s Capsules & Health Ingredients division. These developments underscore companies’ eagerness to strengthen pipelines and expand manufacturing capacities, indicating a dynamic shift in the industry landscape.

In Depth

Key Findings

The first half of 2026 saw a substantial increase in mergers and acquisitions within the pharmaceutical and biopharmaceutical sectors, with several multi-billion dollar deals leading the charge. Highlighting this trend were Sun Pharma’s $11.75 billion acquisition of Organon and Merck KGaA’s $11.3 billion purchase of Bio-Techne, marking them as the largest transactions of the period. These acquisitions unequivocally demonstrate a clear intent from companies to bolster their portfolios and accelerate growth strategies.

Technical / Clinical Details

Significant activity was also observed in the Contract Development and Manufacturing Organization (CDMO) space, where Lonza’s Capsules & Health Ingredients division was acquired by private equity firm Lone Star Funds for $2.2 billion. This transaction reflects a broader trend among CDMOs to divest non-core assets and concentrate resources on strategic, high-growth areas such as biologics manufacturing. Such M&A moves are anticipated to streamline supply chains and enhance efficiency, especially as securing biopharmaceutical development and manufacturing capacity becomes increasingly critical.

Background & Context

The resurgence of M&A in the pharmaceutical industry is primarily driven by the need to counter revenue erosion from patent expirations, fortify pipelines, and gain access to novel technologies. Major pharmaceutical companies are actively acquiring biotechnology firms with innovative drug candidates and new modalities to secure future growth drivers. Amid escalating market uncertainties, there’s a discernible trend towards more strategic consolidations and selective acquisitions aimed at optimizing portfolios and operational efficiencies.

Strategic Significance & Outlook

This robust M&A trend is expected to continue as a dominant theme in the pharmaceutical industry. Investments and acquisitions are likely to increase, particularly targeting companies with cutting-edge technologies in cell and gene therapies, RNA medicines, and AI-driven drug discovery. Furthermore, intensified global competition will compel companies to pursue both economies of scale and specialized expertise, aiming to establish stronger market positions. This ongoing restructuring is set to reshape the industry’s landscape and potentially foster new leadership dynamics.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime